Author Archives: Marta Figueiredo PhD

Oral Anavex 2-73 Eases Dementia, Disease Symptoms in Phase 2 Trial

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) leads to clinically meaningful cognitive improvements while reducing motor and non-motor symptoms in people with Parkinson’s disease dementia (PDD), according to data from a Phase 2 trial. These benefits also significantly associated with increases in the levels of sigma-1 receptor (SIGMAR1),…

Simple Reading Task May Help Detect Early Disease

Assessing vowel percentage, or duration, during a simple reading task is an effective method to detect changes in speech rhythm at early stages of Parkinson’s disease, according to a small study from Italy. Notably, such rhythmic differences between early-stage Parkinson’s patients and healthy individuals were not as pronounced during…

Apomorphine as Steady Infusion of Benefit in Advanced Parkinson’s

Two years of continuous treatment with apomorphine as an under-the-skin infusion safely preserved quality of life and effectively eased motor fluctuations in people with advanced Parkinson’s disease, according to a single-center, real-life study in France. Notably, patients with poor life quality before starting with continuous apomorphine were more likely to improve in…

Survey: Patients Want Low Cost, Under-the-tongue Treatment

When choosing on-demand treatments for “off” episodes, individuals with Parkinson’s disease prefer those with lower out-of-pocket cost and an under-the-tongue (sublingual) mode of administration, according to a survey of 300 patients living in the U.S. Next in preferred features was faster onset, followed by longer duration of “on” periods. These…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums